A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
Trial details
- Registry ID
- NCT05032040
- Drugs studied
- vudalimab
TrialRedline tracks 4 clinical trials sponsored by Xencor, Inc.: 3 Phase 2, 1 Phase 1 / 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary MalignanciesNCT05032040 | vudalimab | Active not recruiting | 2025-10-15Estimated |
| XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate CancerNCT05005728 | vudalimab + cabazitaxel or docetaxel, vudalimab + carboplatin + cabazitaxel, vudalimab + docetaxel, vudalimab + olaparib and 1 more | Completed | 2025-06-10Actual |
| Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)NCT05328102 | Lenalidomide, Plamotamab, Tafasitamab | Terminated | 2023-02-21Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study of XmAb942 in Healthy Participants and Participants With Ulcerative ColitisNCT06619990 | XmAb942 | Recruiting | 2027-12Estimated |
Names as written in the registry records.